A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
-
- STATUS
- Recruiting
-
- sponsor
- BMS
Summary
A Randomized, Multicenter, Double Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) after Completion of Platinum-based First Line Chemotherapy
Description
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in subjects with Small Cell Lung Cancer (SCLC).
BMS would like to find out from this study if nivolumab or nivolumab with ipilimumab helps improve the survival of patients with SCLC, and if it can delay the progression of lung cancer when compared to placebo.
Nivolumab (Opdivo ™) has been approved by the FDA for the treatment of metastatic melanoma (a type of skin cancer) and a different type of previously treated advanced lung cancer. Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body’s immune system to work against tumor cells.
Details
| Condition | Small Cell Lung Cancer |
|---|---|
| Clinical Study Identifier | TX143662 |
| Sponsor | BMS |
| Last Modified on | 23 November 2020 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer